Literature DB >> 1253180

Increased cell killing by metronidazole and nitrofurazone of hypoxic compared to aerobic mammalian cells.

J K Mohindra, A M Rauth.   

Abstract

Nitromidazole and nitrofuran derivatives comprise a large family of compounds, some of which have been shown to be hypoxic cell specific radiosensitizers in vivo and in vitro. The effects of metronidazole (2-methyl-5-nitroimidazole-1-ethanol) and nitrofurazone (5-nitro-2-furaldehyde semicarbazone) were studied on cell viability in vitro in the presence of air or nitrogen in the absence of radiation. Exponential-phase Chinese hamster ovary cells were placed in suspension culture in complete medium in the presence of air, made hypoxic by flowing nitrogen (less then 0.001% oxygen), and exposed to various concentrations of these drugs. As a function of time, aliquots were removed and plated to determine cell viability. After 8 hr of incubation of Chinese hamster ovary cells in 29 mM metronidazole or 500 muM nitrofurazone, the absolute plating efficiency remains relatively constant (80 to 40%) in the presence of air. In contrast, under hypoxic conditions the plating efficiency of the cells dropped to 1% after 6 hr of incubation in 29 mM metronidazole or 500 muM nitrofurazone. This phenomenon of hypoxic cell specific toxicity was found to be dependent upon cell type, concentration of drug, temperature of incubation, and oxygen concentration. The results of these experiments indicate an increased toxicity of these drugs under hypoxic conditions and suggest that further investigation into the mechanism and specificity of these effects is warranted.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1253180

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  38 in total

Review 1.  Nitroimidazoles as hypoxic cell radiosensitizers and hypoxia probes: misonidazole, myths and mistakes.

Authors:  Peter Wardman
Journal:  Br J Radiol       Date:  2018-03-20       Impact factor: 3.039

2.  The effect of 3-(biphenyl-4-yl)-3-hydoxyquinuclidine (BPQ-OH) and metronidazole on Trichomonas vaginalis: a comparative study.

Authors:  Débora Afonso Silva Rocha; Ivone de Andrade Rosa; Julio A Urbina; Wanderley de Souza; Marlene Benchimol
Journal:  Parasitol Res       Date:  2014-04-22       Impact factor: 2.289

Review 3.  The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents.

Authors:  Dietmar W Siemann
Journal:  Cancer Treat Rev       Date:  2010-06-08       Impact factor: 12.111

Review 4.  Targeting hypoxia in cancer therapy.

Authors:  William R Wilson; Michael P Hay
Journal:  Nat Rev Cancer       Date:  2011-06       Impact factor: 60.716

5.  Sister chromatid exchanges in peripheral lymphocytes of urinary tract infection treated with nitrofurantoin.

Authors:  S Sardaş; A Metin; S Gök; A E Karakaya; N Aykol
Journal:  Int Urol Nephrol       Date:  1990       Impact factor: 2.370

6.  Cytotoxicity of glucose analogues in V79 multicell spheroids.

Authors:  R Sridhar; E C Stroude; W R Inch
Journal:  In Vitro       Date:  1979-09

7.  Absence of strand breaks in deoxyribonucleic acid treated with metronidazole.

Authors:  N F LaRusso; M Tomasz; D Kaplan; M Müller
Journal:  Antimicrob Agents Chemother       Date:  1978-01       Impact factor: 5.191

8.  Relationship between metronidazole metabolism and bactericidal activity.

Authors:  E J Chrystal; R L Koch; M A McLafferty; P Goldman
Journal:  Antimicrob Agents Chemother       Date:  1980-10       Impact factor: 5.191

9.  Metronidazole decreases viability of DLD-1 colorectal cancer cell line.

Authors:  Anna Sadowska; Rafał Krętowski; Beata Szynaka; Marzanna Cechowska-Pasko; Halina Car
Journal:  Cancer Biother Radiopharm       Date:  2013-06-18       Impact factor: 3.099

10.  A simple and inexpensive method to control oxygen concentrations within physiological and neoplastic ranges.

Authors:  P G Penketh; K Shyam; R P Baumann; E S Ratner; A C Sartorelli
Journal:  Anal Biochem       Date:  2015-09-08       Impact factor: 3.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.